COVID-19 Vaccination-Associated Myocarditis in Adolescents


DOI: 10.1542/peds.2021-053427

Journal: Pediatrics

Article Type: Regular Article


This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.
COVID-19 Vaccination-Associated Myocarditis in Adolescents

Supriya S. Jain\textsuperscript{a}, MD, Jeremy M. Steele\textsuperscript{b}, MD, Brian Fonseca\textsuperscript{c}, MD, Sihong Huang\textsuperscript{d} MD, MMsc, Sanket Shah\textsuperscript{c} MD, Shiraz A. Maskatia\textsuperscript{f} MD, Sujatha Buddhe\textsuperscript{g}, MD, MS., Nilanjana Misra\textsuperscript{h} MBBS, Preeti Ramachandran\textsuperscript{i} MD, Lasya Gaur\textsuperscript{j} MD, Parham Eshtehardi\textsuperscript{k} MD, Shafkat Anwar\textsuperscript{l} MD, Neeru Kaushik\textsuperscript{m} MD, Frank Han\textsuperscript{n} MD, Nita Ray Chaudhuri\textsuperscript{o} MD, Lars Grosse-Wortmann\textsuperscript{p} MD

Affiliations: \textsuperscript{a}New York Medical College, Maria Fareri Children’s Hospital at Westchester Medical Center, Valhalla, New York, \textsuperscript{b}Yale University School of Medicine, New Haven, Connecticut, \textsuperscript{c}Colorado Children’s Hospital, Aurora, Colorado, \textsuperscript{d}Helen DeVos Children’s Hospital, Michigan State University College of Human Medicine, Spectrum Health, Grand Rapids, Michigan, \textsuperscript{e}Children’s Mercy Hospital, Kansas City, Missouri, \textsuperscript{f}Stanford University School of Medicine, Lucile Packard Children’s Hospital, Palo Alto, California \textsuperscript{g}Seattle Children’s Hospital, University of Washington, Seattle, Washington, \textsuperscript{h}Cohen Children’s Medical Center of New York, Northwell Health, Queens, New York, \textsuperscript{i}University of Kentucky, Lexington, Kentucky, \textsuperscript{j}John Hopkins School of Medicine, Baltimore, Maryland, \textsuperscript{k}Northside Heart and Vascular Institute, Northside Hospital, Atlanta, Georgia, \textsuperscript{l}University of California at San Francisco, San Francisco, California, \textsuperscript{m}UCSF Benioff Children’s Hospitals, Oakland, California, \textsuperscript{n}University of Illinois Chicago, College of Medicine at Peoria, Illinois, \textsuperscript{o}West Virginia University, Morgantown, West Virginia, \textsuperscript{p}Oregon Health and Science University, Portland, Oregon

Address correspondence to: Supriya S. Jain MD, Department of Pediatrics, Division of Pediatric Cardiology, New York Medical College, Maria Fareri Children’s Hospital at Westchester Medical Center

100 Woods Road, Valhalla, New York, 10595, Sjain7@nymc.edu, 914-594-2222.

Conflict of Interest Disclosures (including financial disclosures): No conflicts of interest to disclose. (All authors)

Funding: This study was not supported by external funding.

Article Summary: Large multi-center study affords us insight into characteristics, early outcomes and myocardial injury, noted on state-of-the-art CMR imaging in children with myocarditis after COVID-19 vaccination.

What’s Known on This Subject: Based on the recent CDC data and smaller case series, there is a temporal association of the second dose of mRNA vaccines against COVID-19 with myocarditis.

What This Study Adds: It enhances our understanding into the spectrum, severity and associated myocardial tissue changes in COVID-19 vaccination associated myocarditis as compared to MIS-C. It provides valuable and timely follow up information in these children.

Contributors’ Statements

Drs. Jain and Grosse-Wortmann conceptualized and designed the study, designed the data collection form, collected data, coordinated, and supervised data collection, carried out the analyses, drafted the initial manuscript, reviewed, and revised the manuscript.

Drs. Steele and Fonseca collected data, helped in editing the initial manuscript and figures, critically reviewed the manuscript for important intellectual content.

Drs. Huang, Shah, Maskatia, Buddhe, Misra, Ramachandran, Gaur, Eshtehardi, Anwar, Kaushik, Han and Chaudhuri collected data, critically reviewed the manuscript for important intellectual content.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Abstract

Objective:
This study aimed to characterize the clinical presentation, short term prognosis, and myocardial tissue changes associated with acute myocarditis following COVID-19 vaccination in the pediatric population.

Methods:
In this retrospective multi-center study across 16 US hospitals, patients <21 years of age with a diagnosis of myocarditis following COVID-19 vaccination were included and compared to a cohort with multisystem inflammatory syndrome in children (MIS-C). Younger children with vaccine associated myocarditis were compared to older adolescents.

Results:
63 patients with a mean age of 15.6 years were included. 92% were male. All had received an mRNA vaccine and, except for one, presented following the 2nd dose. Four patients had significant dysrhythmia. 14% had mild left ventricular dysfunction on echocardiography which resolved on discharge. 88% met the diagnostic cardiac magnetic resonance (CMR) Lake Louise criteria for myocarditis. Myocardial injury was more prevalent in comparison to MIS-C patients. None of the patients required inotropic, mechanical, or circulatory support. There were no deaths. Follow up data obtained in 86% of patients, at a mean of 35 days showed resolution of symptoms, arrhythmias, and ventricular dysfunction.

Conclusions:
Clinical characteristics and early outcomes are similar between the different pediatric age groups. There is evidence of myocardial inflammation and injury following mRNA COVID-19 vaccination as seen on CMR. The hospital course is mild with quick clinical recovery and excellent short-term outcomes. Close follow up and further studies are needed to understand the long-term implications and mechanism of these myocardial tissue changes.
Introduction

Recently, an association of mRNA based COVID-19 vaccine with myocarditis has been reported.\textsuperscript{1-3} In June 2021, the Centers for Disease Control and Prevention (CDC) observed a rate of post-vaccine myocarditis that was higher in adolescents and young adults than the expected baseline.\textsuperscript{3} Thus far, only small case series in the pediatric population with rudimentary information about the myocardium have been reported.\textsuperscript{1} The current study aimed to understand the spectrum and severity of this recently recognized condition in the young, to evaluate the associated myocardial tissue changes and to compare it to the degree of cardiac involvement seen in multisystem inflammatory syndrome in children (MIS-C).

Methods

Following the initial reports of a possible association between COVID-19 vaccines and myocarditis, a call went out to physicians who specialize in cardiovascular imaging around the nation to report such cases from their institution to this retrospective study. Most investigators are clinical pediatric cardiologists and cardiac magnetic resonance (CMR) experts. The cases were reported to CDC’s Vaccine Adverse Event Reporting System (VAERS) at the respective centers. The local research ethics boards of several of the participating centers issued an IRB exemption, while written informed consent was obtained from patients and/or their guardians at the others. Patients \( \leq 21 \) years of age with a diagnosis of acute myocarditis, based on clinical presentation, abnormal biomarkers and/or cardiovascular imaging findings within 2 weeks of COVID-19 vaccination were included. Demographic information (including race/ethnicity to learn how different populations may be impacted), clinical presentation, cardiovascular imaging findings,
viral testing including comprehensive viral serology, hospital course, and follow-up information were collected. Patients with a plausible alternative etiology for their myocarditis including a concurrent acute viral infection were excluded.

From the CMR studies, ventricular volumes, and ejection fraction (EF) were obtained. The 2009 Lake Louise criteria\textsuperscript{4} or, where parametric mapping was available, the 2018 revised Lake Louise CMR criteria were used to test for a diagnosis of acute myocarditis.\textsuperscript{5,6} (Appendix). Evidence of myocardial edema was determined based on abnormally high signal intensity on T2-weighted imaging or prolonged T2 relaxation time on T2 mapping. Hyperemia was determined by myocardial early gadolinium enhancement (EGE). Native T1 times, extracellular volume (ECV) fraction and myocardial late gadolinium enhancement imaging (LGE) were collected as markers of cardiomyocyte injury and necrosis. Consistent with Society for Cardiovascular Magnetic Resonance guidelines, native T1 results were only used if institutional normal ranges were available and converted into categorical values.\textsuperscript{7} CMR image analysis and interpretation were done by the performing center to best reflect real-world practice. The study was not intended to identify and/or track pericarditis and focused on the clinical and imaging characteristics of COVID-19 vaccine associated myocarditis (C-VAM).

To gain perspective about the observed myocardial tissue changes, patients with a diagnosis of multisystem inflammatory syndrome in children (MIS-C) who had undergone CMR with a myocarditis protocol during their acute/sub-acute phase of illness were included for comparison from few select centers. As obtaining CMR data in the acute phase of illness in MIS-C had been
logistically challenging earlier due to the risk of exposure of severe acute respiratory syndrome virus-2 (SARS-COV-2) to others, this data was limited. Statistical Analysis: Data are presented as means and standard deviations if normally distributed, as medians and ranges otherwise, or as counts and percentages as applicable. Older vs. younger adolescents with C-VAM and patients with MIS-C vs. C-VAM were compared using unpaired, two-tailed Student T tests. P values <0.05 were regarded as statistically significant.

Results

Clinical Characteristics

Sixty-nine cases of patients with a diagnosis of acute myocarditis following COVID-19 vaccination who had presented between March 2021 and June 2021 were submitted from 16 institutions. Six patients were excluded with a possible concurrent acute infection which could have caused the myocarditis. Sixty-three patients with a mean age of 15.6±1.8 years (range 12-20 years) were included. Thirty-one patients (49%) were in the 12-15 age group. Fifty-eight patients (92%) were male. Forty-three (68%) were White, 9 (14%) were Hispanic, 3 (5%) of Asian descent, 2 (3%) reported as other and 6 (10%) were unreported. All patients had been previously healthy before receiving the vaccine, without any viral prodrome. None of the patients had a history of or reactions to prior vaccines. Fifty-five (87%) had no significant past medical history. Pertinent past medical history in seven patients included a remote history of viral myocarditis in two patients, juvenile idiopathic arthritis, eosinophilic esophagitis, hyperlipidemia, irritable bowel syndrome and Wolff-Parkinson-White syndrome in one each.
One patient had a history of mild COVID-19 infection six months prior to his first dose of vaccine with no residual symptoms. There was a family history of viral myocarditis and Brugada syndrome in one patient each. Fifty-nine patients (94%) had received the Pfizer-BioNTech vaccine and four (6%) had received the Moderna vaccine. All except for one patient presented following the 2nd dose. The patient who presented after the initial dose had no known prior COVID-19 infection.

Mean onset of symptoms from day of vaccination was 2.1±1.3 days (range 0-7 days). Forty-five patients (71%) presented with symptoms within two days of receiving the vaccine. Predominant symptoms are summarized in Table 1. All patients displayed elevated serum troponin levels and all, but one had abnormal C-reactive protein levels. Approximately half of the patients had an elevated erythrocyte sedimentation rate (44%) and/or B-natriuretic peptide (53%). Acute COVID-19 infection was ruled out based on a negative real-time reverse transcription polymerase chain reaction (RT-PCR) test to detect SARS-COV-2 in 56 patients (89%); the others were not tested. Past exposure to COVID-19 infection was ruled out based on negative nucleocapsid antibody test in 53 (84%) patients. Of these, 18 patients were positive for spike protein, suggesting an active immune response to the vaccine.

The length of stay in the hospital was 3.0±1.4 days (range 1-7). Twenty-seven (43%) patients were supervised in the intensive care unit (ICU) during their hospitalization, mainly for arrhythmia monitoring with a mean stay of 2.5 days. None of the patients required inotropic support, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
no deaths. Treatments included nonsteroidal anti-inflammatory drugs in 54 patients (86%), intravenous immunoglobulin in 17 (23%), corticosteroids in 15 (24%) and colchicine in four (6%). Six patients (10%) had received aspirin, clopidogrel, nitroglycerine, heparin, or beta blocker due to concerns for ST-segment elevation myocardial infarction on presentation.

### Cardiovascular Findings

Forty-four patients (70%) had abnormal electrocardiograms (ECGs). Predominantly diffuse ST segment elevations and/or T wave inversion were noted (Figure 1). One patient (2%) presented with complete heart block but did not require pacing and regained normal conduction following admission. Three (5%) patients were noted to have non-sustained ventricular tachycardia, of which one was treated with amiodarone (Figure 2), and another with an oral beta-blocker.

Nine patients (14%) had mildly decreased left ventricular function (EF 45-54%) by echocardiography (Table 2). Coincidental findings on echocardiography included bicuspid aortic valve and an anomalous origin of the right coronary artery from the left sinus of Valsalva in one patient each. Fifty-six patients (89%) underwent CMR. The CMR study was performed within a week of the COVID-19 vaccination in 51 patients (91%). Fifty (89%) patients had evidence of myocardial edema based on T2-weighted imaging or T2 mapping (Figure 3). T1-weighted imaging to evaluate EGE denoting hyperemia was performed in 13 patients (21%) and was universally negative. Forty-nine patients (88%) had evidence of LGE (Figures 4&5) which occurred nearly uniformly in the inferolateral and lateral walls of the left ventricle in the subepicardial region, typical location encountered in myocarditis and a pattern consistent with non-
ischemic myocardial injury and necrosis.\textsuperscript{9} LGE were predominantly reported in the American Heart Association myocardial segments 4, 5, 6, 10, 11, 12 along with segments 1, 13, 14,15,16 in some patients.\textsuperscript{10} Mean ECV was 32.6±9.0%. Thirteen patients (23\%) had mildly reduced left ventricular function while three (7\%) had mildly reduced right ventricular function. Mildly increased left ventricular volume was reported in one patient, while three had borderline/mild right ventricular dilation.\textsuperscript{11,12} Forty-nine patients (88\%) fulfilled the CMR Lake Louise imaging criteria for myocarditis.

There was no significant difference in the clinical characteristics or the cardiovascular findings between the 12–15-year age group and the older adolescents in the C-VAM cohort (Table 1&2). On comparison of the patients with C-VAM to the MIS-C cohort (Table 3), the MIS-C patients were sicker with a longer ICU length of stay, 7 days ±5 (2-18). 50\% of them required inotropic support including ECMO in one. C-reactive protein was higher and ventricular function was worse when compared to patients with C-VAM. Serum troponin levels were higher and there was increase in prevalence and extent of LGE in the C-VAM group when compared to the MIS-C cohort (Figures 4, 5& 6)

**Follow up**

In patients with COVID-19 vaccine associated myocarditis, follow up data until July 21, 2021, was reviewed. There was no significant difference in the follow up/ short-term outcomes
between the younger and older pediatric age groups. Fifty-four patients (86%) were evaluated for follow up at a mean of 35 days ±25 (8-122) since their last vaccination. All were doing well clinically with resolution of their symptoms in most. Seven patients (13%) reported non-specific symptoms including intermittent atypical chest pain (4), palpitations (2) and mild fatigue with minimal activity (1). All patients had normal ventricular function, based on echocardiography. The 4 patients who had presented with arrhythmias earlier continue to be in normal sinus rhythm with no recurrence. Of the 60 patients with ECGs done at follow-up, 48 (80 %) had normal ECGs. Eight had persistent T wave abnormality/inversion in inferior leads, two had inferior Q waves, and two had non-specific ST-T changes. Holter information was available in 10 patients (19%) and revealed no abnormalities. Troponin levels were obtained in 27 patients (50%) and were normal, except three individuals had borderline elevations. 2 patients (4%) have had a follow up CMR so far at 66 and 71 days, respectively, after the initial CMR. Both showed improvement in myocardial edema but had persistence of LGE with mild improvement in one patient (Figure 7). Both patients continued to have normal biventricular function on CMR. Biventricular sizes were normal in both, including one who was noted to have mild right ventricular dilation at his initial CMR. Follow up CMR studies have been scheduled and are pending at the time of this submission for rest of the patients. There were no acute events, rehospitalization or deaths reported.

Discussion

Although myocarditis following immunizations against smallpox, influenza, and tetanus is well recognized, \(^{13-16}\) the experience in children with vaccine associated myocarditis, other than following COVID-19 vaccination is limited. Importantly, myocarditis was not reported following
the clinical trials of mRNA COVID-19 vaccines.\textsuperscript{17,18} This may be related to the limited number of patients in the clinical trials and reflective of the apparent rarity of this complication.\textsuperscript{19}

On May 10, 2021, the U.S. Food and Drug Administration (FDA) expanded the Emergency Authorization Use for the Pfizer-BioNTech vaccine to include adolescents 12 through 15 years age.\textsuperscript{20} As of July 6, 2021, 594 cases of myocarditis/pericarditis reported to VAERS have been confirmed by CDC and FDA.\textsuperscript{21} Based on the Advisory Committee on Immunization Practices notification from June 23, 2021, the highest reporting rates were among males aged 12−17 years and those aged 18−24 years (62.8 and 50.5 reported myocarditis cases per million second doses of mRNA COVID-19 vaccine administered, respectively)\textsuperscript{22} At present, the CDC and FDA continue to recommend the COVID-19 vaccination for all individuals aged \( \geq 12 \) years.\textsuperscript{22}

The present study adds the following information to our understanding of myocarditis related to the COVID-19 vaccine:

1. Myocarditis following mRNA vaccines is associated with acute myocardial injury and edema of the myocardium, in the presence of preserved ventricular function.
2. The initial clinical course and short-term outcomes are good and reassuring.
3. There is no apparent difference in clinical characteristics and outcomes between 12–15-year-olds and older adolescents.
4. The clinical picture is distinct from multisystem inflammatory syndrome in children (MIS-C) and appears to be less severe.
While endomyocardial biopsy remains the confirmatory test in the diagnosis of myocarditis, its invasive nature, and the possibility of tissue sampling errors along with risks of cardiac perforation and arrhythmias limit its use, especially in children. Cardiac magnetic resonance imaging has emerged as the modality of choice to evaluate the myocardium, including in myocarditis. The CMR diagnosis of myocarditis by the Lake Louise Criteria is based on the detection of myocardial edema and myocardial injury/necrosis. Majority of our patients met this CMR criteria, rest were classified as clinically suspected myocarditis. Prior reports provided limited insights into the CMR findings in C-VAM. The myocardial tissue characteristics observed in our patients were like those seen in acute viral-mediated myocarditis. Most patients presented with evidence of myocardial edema. Subepicardial LGE, affecting the left ventricular lateral and inferior walls was present in nearly all patients. The high prevalence of LGE and, in some cases, its extent along with consistency of LGE pattern (Figures 4 & 5) was unexpected, especially given the relatively mild clinical symptoms in many patients, although it was in keeping with the elevated troponin levels that were observed in all patients. The relatively mild disease course of the patients reported here makes it tempting to speculate that many others go undetected, as was the case with the smallpox vaccine.

In contrast, patients with MIS-C are often critically ill on presentation requiring advanced support. They have higher systemic inflammatory markers and imaging evidence of cardiodepression. The C-VAM patients, with a milder presentation/hospital course and relatively preserved ventricular function appear to have increased prevalence of LGE in comparison to MIS-C. This raises the question if differing pathomechanisms of cardiac involvement are at play in C-VAM versus MIS-C. While it has been hypothesized that the acute ventricular dysfunction
complicating MIS-C may be related to the systemic cytokine storm that is present during this overwhelming inflammatory condition\textsuperscript{25-28}, the mechanism of cardiac injury in C-VAM appears more targeted to the cardiomyocyte. The pathophysiology of the myocardial injury in these patients is not well understood. One proposed mechanism is through molecular mimicry\textsuperscript{29-31}: Myocardial proteins may resemble those which are expressed after mRNA vaccination, to which the body mounts an antibody response, possibly leading to myocardial injury/inflammation. The spike glycoprotein of SARS-COV-2 attaches to the myocardial type 2 angiotensin-converting enzyme (ACE2) receptor expressed by cardiomyocytes, directly causing cell membrane disruption, even at low viral load\textsuperscript{32,33} Thus as an alternative explanation of vaccine related injury, it is conceivable that in C-VAM patients, the myocardial injury may be the result of SARS-COV-2 spike protein encoded by the mRNA vaccine and its binding to the host cell ACE2 receptor\textsuperscript{34} even in the absence of live virus. Lastly, it is possible that the complex of mRNA vaccine induced spike protein and myocardial ACE2 receptor presents an immunological target. In this context, the striking predilection for males, which is a consistent element of previous reports and corroborated by our results, is noteworthy: Less than 10\% of our patients were female. Estrogen is known to upregulate ACE2\textsuperscript{35} which has been proposed as a protective mechanism against organ damage by SARS-COV-2, including in the heart. An increased genetic susceptibility in some patients has been discussed\textsuperscript{36} and may explain the recurrent myocarditis in two of our patients who had a previous episode and potentially a third with a family history of viral myocarditis.

Myocarditis after COVID-19 vaccination has been noted predominantly in White patients, in contrast to the Black and ethnic minority groups frequently reported in MIS-C\textsuperscript{25,27,28}
explanations for this ethnic discrepancy may include socioeconomic disparities seen in COVID-19 infections, variation in vaccination rates, as well as susceptibility to the infection itself and/or its complications.

Ten percent of our patients were initially worked-up and treated for myocardial infarction. As awareness of vaccine related myocarditis increases, we expect that more practitioners will consider the possibility of C-VAM, and the diagnosis will be made earlier.

A selection bias in the C-VAM cohort towards LGE positive patients cannot be ruled out in our study, given that LGE was likely used to establish a diagnosis of myocarditis in some individuals. In fact, a similar selection bias is likely present in most if not all CMR based studies of myocarditis. The true and independent prevalence of LGE is therefore unknown and we are unable to speculate whether LGE is more prevalent after vaccination as compared to viral myocarditis.

The prognostic significance of the prevalent LGE in asymptomatic C-VAM patients is unclear at this time. The follow up CMR in two of our patients has shown persistence of LGE, albeit mildly decreased in one. Some reports have suggested a contraction of LGE during follow-up of acute viral myocarditis. Follow up CMR hence appears warranted to depict the extend of myocardial and ventricular remodeling/resolution of LGE. In the absence of guidelines for return to sports after myocarditis following COVID-19 vaccination, our findings make it seem reasonable to apply the recommendations available for acute viral myocarditis which include refraining from sports for at least three to six months as well as close observation and monitoring for any dysrhythmias.
Limitations of our study include its retrospective nature, combining patients from 16 different institutions which used similar, but not identical approaches during the work-up and management of childhood myocarditis. Our cases represent a selected cohort which may not necessarily be representative of the general pediatric population.

**Conclusion**

We report the largest study that we are aware of describing myocardial tissue characteristics in detail as noted on CMR with clinical features and early outcomes in pediatric patients with acute myocarditis following mRNA COVID-19 vaccination in the United States. Comparison with MIS-C improves our understanding of both the disease processes. Most patients with COVID-19 vaccine associated myocarditis had evidence of myocardial edema and of myocardial injury as evidenced by LGE which was out of keeping with the mild clinical presentation and normal or quickly recovered ventricular function in most. Early clinical outcomes in these patients have been reassuring so far. The prognostic significance, long-term implications and mechanism of this myocardial injury needs to be studied further, especially as vaccination efforts are rolled out to younger children.

**Acknowledgments**

Thank you to Dr. Michael H. Gewitz (Maria Fareri Children’s Hospital at Westchester Medical Center) for his review of the manuscript and continued support.
References


23. Law YM, Lal AK, Chen S, et al. on behalf of the American Heart Association Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Stroke Council, Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. Circulation, July 7, 2021(published ahead of print) [https://doi.org/10.1161/CIR.0000000000001001](https://doi.org/10.1161/CIR.0000000000001001)


38. Reporting COVID-19 Vaccination Demographic Data, cdc.gov, Updated June 28, 2021


Table 1: Clinical characteristics in children and young adults with myocarditis following COVID-19 vaccination

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=63)</th>
<th>12-15 years (n=31)</th>
<th>16-20 years (n=32)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>15.6±1.8 (12-20)</td>
<td>14.4±1.1</td>
<td>16.9±1.0</td>
<td></td>
</tr>
<tr>
<td>Height (cm.)</td>
<td>172±11</td>
<td>169±11</td>
<td>176±10</td>
<td>0.01</td>
</tr>
<tr>
<td>Weight (kg.)</td>
<td>73.3±19.4</td>
<td>67.5±16.6</td>
<td>79±20.5</td>
<td>0.02</td>
</tr>
<tr>
<td>BSA (m2)</td>
<td>1.86±0.30</td>
<td>1.77±0.30</td>
<td>1.95±0.30</td>
<td>0.008</td>
</tr>
<tr>
<td>Male sex n, (%)</td>
<td>58 (92)</td>
<td>27 (87)</td>
<td>31 (97)</td>
<td>0.16</td>
</tr>
<tr>
<td>2nd dose n, (%)</td>
<td>62 (98)</td>
<td>30</td>
<td>32</td>
<td>0.32</td>
</tr>
<tr>
<td>Days from recent vaccination to symptoms onset</td>
<td>2.1±1.3 (0-7)</td>
<td>1.9±0.9 (1-3)</td>
<td>2.3±1.7 (0-7)</td>
<td>0.15</td>
</tr>
<tr>
<td>Symptoms: n, (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onset &lt; 2 days since vaccination</td>
<td>45 (71)</td>
<td>22 (71)</td>
<td>23 (72)</td>
<td>0.94</td>
</tr>
<tr>
<td>Fever (100.4 F and above)</td>
<td>28 (44)</td>
<td>13 (42)</td>
<td>15 (47)</td>
<td>0.70</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>22 (35)</td>
<td>9 (29)</td>
<td>13 (41)</td>
<td>0.34</td>
</tr>
<tr>
<td>Chest pain</td>
<td>63 (100)</td>
<td>31 (100)</td>
<td>32 (100)</td>
<td>1.0</td>
</tr>
<tr>
<td>Nausea/Emesis</td>
<td>15 (24)</td>
<td>7 (23)</td>
<td>8 (25)</td>
<td>0.82</td>
</tr>
<tr>
<td>Headache</td>
<td>16 (25)</td>
<td>7 (23)</td>
<td>9 (28)</td>
<td>0.62</td>
</tr>
<tr>
<td>Fatigue/Myalgias/Arthralgias</td>
<td>24 (38)</td>
<td>8 (26)</td>
<td>16 (50)</td>
<td>0.05</td>
</tr>
</tbody>
</table>
### Laboratory values:

<table>
<thead>
<tr>
<th>Test</th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troponin (ng/mL)</td>
<td>8.8±9.1</td>
<td>7.7±4.8</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>37±35</td>
<td>28±23</td>
</tr>
<tr>
<td>BNP (pg/mL)</td>
<td>94±147</td>
<td>109±168</td>
</tr>
</tbody>
</table>

### Treatment/Hospital course:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n/total n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIG</td>
<td>17(23)</td>
</tr>
<tr>
<td>Steroids</td>
<td>15(24)</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>54(86)</td>
</tr>
<tr>
<td>Colchicine</td>
<td>4(6)</td>
</tr>
<tr>
<td>ICU admissions</td>
<td>27 (43)</td>
</tr>
<tr>
<td>Length of ICU in days</td>
<td>2.5±1.5</td>
</tr>
<tr>
<td>Length of hospital stay in days</td>
<td>3.0±1.4</td>
</tr>
<tr>
<td>Inotropic/mechanical/circulatory</td>
<td>0</td>
</tr>
<tr>
<td>ECMO, Mortality</td>
<td></td>
</tr>
</tbody>
</table>

*Data reported as mean, standard deviation, range unless specified.

Percentages may not total hundred because of rounding.

Unless otherwise specified, the denominator for calculation of percentages is the total sample size.

**Abbreviations:** BSA: Body surface area, BNP: B-natriuretic peptide, IVIG: Immunoglobulin, NSAIDs: Nonsteroidal anti-inflammatory drugs, ICU: intensive care unit
Table 2: Cardiovascular testing/imaging findings in children and young adults with myocarditis following COVID-19 vaccination

<table>
<thead>
<tr>
<th>Findings</th>
<th>Overall (n=63)</th>
<th>12-15 years (n=31)</th>
<th>16-20 years. (n=32)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG: n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormalities on ECG</td>
<td>44 (70)</td>
<td>19 (61)</td>
<td>25 (78)</td>
<td>0.38</td>
</tr>
<tr>
<td>Complete Heart Block</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>1 (3)</td>
<td>0.32</td>
</tr>
<tr>
<td>Non sustained VT</td>
<td>3 (5)</td>
<td>1 (3)</td>
<td>2 (6)</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Echocardiography:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV EF %</td>
<td>61 ±6.5 (45-73)</td>
<td>61 ±6 (45-73)</td>
<td>60 ±7 (45-83)</td>
<td>0.51</td>
</tr>
<tr>
<td>Reduced LV EF, n, (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (EF:45-54%)</td>
<td>9 (14)</td>
<td>4 (13)</td>
<td>5 (16)</td>
<td>0.80</td>
</tr>
<tr>
<td>Moderate (EF:35-44%)</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (EF &lt;35%)</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CMR:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from recent Vaccination to CMR</td>
<td>4.9±2.3 (2-15)</td>
<td>5.0±2.8 (2-15)</td>
<td>5.2±3.2 (2-15)</td>
<td>0.68</td>
</tr>
<tr>
<td>Myocardial Edema (T2 weighted imaging/T2 mapping) n, total n (%)</td>
<td>50/56 (89)</td>
<td>24/28 (86)</td>
<td>26/28 (93)</td>
<td>0.40</td>
</tr>
<tr>
<td>ECV%</td>
<td>32.6±9</td>
<td>36.3±11</td>
<td>28.9±4</td>
<td>0.05</td>
</tr>
<tr>
<td>Presence of LGE n, total n (%)</td>
<td>49/56 (88)</td>
<td>24/28 (86)</td>
<td>25/28 (89)</td>
<td>0.69</td>
</tr>
<tr>
<td>LV EF %</td>
<td>58 ±6 (46-73)</td>
<td>59 ±6 (46-73)</td>
<td>57 ±5 (47-64)</td>
<td>0.21</td>
</tr>
<tr>
<td>Reduced LV EF, n, (%)</td>
<td>Mild (EF:45-54%)</td>
<td>Moderate (EF:35-44%)</td>
<td>Severe (EF &lt;35%)</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>13/56 (23)</td>
<td>6/28 (21)</td>
<td>7/28 (25)</td>
<td>0.83</td>
<td></td>
</tr>
</tbody>
</table>

| LV EDV ml/m2 | 86±12 (55-111) | 85 ± 11 (57-105) | 88±14 (55-111) | 0.40 |

| RV EF %       | 56 ±9 (43-105) | 56 ± 5 (47-65)  | 55 ±12 (43-105) | 0.68 |

| Reduced RV EF (EF<49%) n, total n (%) | 3/45 (7) | 1/22 (5) | 3/23 (13) | 0.58 |

| RV EDV ml/m2 | 89±15 (48-123) | 87 ± 13 (56-107) | 91±16 (48-123) | 0.36 |

*Data reported as mean, standard deviation, range unless specified.*

Percentages may not total hundred because of rounding.

Unless otherwise specified, the denominator for calculation of percentages is the total sample size.

**Abbreviations:** ECG: Electrocardiogram, VT: Ventricular tachycardia, LV: Left ventricle, RV: Right ventricle, EF: ejection fraction, EDV: end-diastolic volume, CMR: cardiac magnetic resonance, ECV: extracellular volume, LGE: late gadolinium enhancement.
### Table 3: Comparison between patients with mRNA COVID-19 vaccine associated myocarditis and MIS-C

<table>
<thead>
<tr>
<th></th>
<th>C-VAM N=63</th>
<th>MIS-C N=16</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>15.6±1.8</td>
<td>13.3±4.3</td>
<td>0.05</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.3±19.4</td>
<td>57.1±20.8</td>
<td>0.01</td>
</tr>
<tr>
<td>Troponin (ng/ml)</td>
<td>8.78±9.15</td>
<td>0.67±1.10</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>37.0±35.4</td>
<td>151.1±119.5</td>
<td>0.002</td>
</tr>
<tr>
<td>Intensive care length of stay</td>
<td>2.5±1.5</td>
<td>6.6±4.6</td>
<td>0.004</td>
</tr>
<tr>
<td>LVEF % (echocardiography)</td>
<td>60.9±6.5</td>
<td>45.1±9.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LGE (n, %)</td>
<td>49 (88)</td>
<td>3 (20)</td>
<td>0.0005</td>
</tr>
<tr>
<td>Myocardial edema* (n, %)</td>
<td>47 (83.9)</td>
<td>4 (28.6)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

* As evidenced by CMR parametric mapping or T2 weighted imaging

**Abbreviations:** LGE: late gadolinium enhancement, LVEF: left ventricular ejection fraction, MIS-C: multisystem inflammatory syndrome in children, C-VAM: COVID-19 vaccine associated myocarditis
Figure 1. ECG in a 17-year-old patient with myocarditis following COVID-19 vaccination showing diffuse ST segment elevation (days 1, 2) and T wave inversion (days 4, 10)
Figure 2. Strips from a telemetry unit showing multiple episodes of non-sustained ventricular tachycardia in a 16-year-old patient with myocarditis following COVID-19 vaccination.
**Figure 3.** CMR examples of myocardial edema in C-VAM cohort:

(A, B) T2 weighted images show high signal intensity in myocardium (yellow arrow) compared to skeletal muscle (*) in 2 patients.

(C) T2 mapping image demonstrates area of elevated T2 (black arrow) in subepicardial, mid-myocardial region corresponding to (D) area of LGE (yellow arrow)
Figure 4. CMR examples illustrating LGE in C-VAM cohort (short axis view): The pattern of LGE is notably similar across all patients with a subepicardial distribution along the lateral, inferolateral and inferior walls in the basal and mid myocardium of the left ventricle (yellow arrows).
Figure 5. CMR examples illustrating LGE in C-VAM cohort (4 chamber view) The pattern of LGE is notably similar across all patients with enhancement in a subepicardial and mid myocardial pattern noted along the lateral and inferior walls (yellow arrows).
Figure 6. CMR images in three children hospitalized for MIS-C (A-C) demonstrating trivial, focal mid-myocardial LGE (white arrows). All 3 patients presented with at least moderate ventricular dysfunction, required inotropic support, including one needing extracorporeal membrane oxygenation ECMO (B)
Figure 7. CMR in a COVID-19 vaccine associated myocarditis patient, at the time of diagnosis (A-D) and 8 weeks post diagnosis (E-H). There is notable persistence of myocardial late gadolinium enhancement (yellow arrows) with mild improvement.
Appendix: CMR Tissue Characterization\textsuperscript{4,5,6,23}

In acute myocarditis, expected tissue pathology includes interstitial/intracellular edema, hyperemia, capillary leak and in severe cases, cardiomyocyte necrosis and subsequent fibrosis.

Cardiac magnetic resonance is useful to visualize tissue changes. It can demonstrate markers of inflammation as well as cardiomyocyte damage.

In inflammation, increased permeability of cellular membrane results in edema. Imaging markers for edema include high signal intensity of cardiac muscle compared to skeletal muscle on T2-weighted imaging (Figure 3 A, B) or increased T2 relaxation time on T2 mapping (Figure 3 C). Rapid uptake of contrast in the myocardium (early gadolinium enhancement) is a sign of hyperemia/capillary leak.

Areas of acute myocardial injury/necrosis or subsequent scarring are detected by contrast retention 10 to 15 minutes after injection of gadolinium contrast agent indicated by late gadolinium enhancement (LGE). (Figure 3 D, Figures 4-7)

As per the 2009 Lake Louise criteria, in clinically suspected cases of myocarditis, the diagnosis is likely if 2 of 3 criteria from elevated signal on T2-weighted imaging, early gadolinium enhancement, and late gadolinium enhancement were present. In 2018, these criteria were updated to include edema markers such as T2 time and fibrosis markers including T1 time, and extracellular volume (ECV) fraction for improved diagnostic accuracy.
COVID-19 Vaccination-Associated Myocarditis in Adolescents

Pediatrics  originally published online August 13, 2021;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2021/08/12/peds.2021-053427.citation

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
COVID-19 Vaccination-Associated Myocarditis in Adolescents

Pediatrics originally published online August 13, 2021;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/early/2021/08/12/peds.2021-053427.citation